Phase III Trial of Coenzyme Q10 in Mitochondrial Disease
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
To show that oral CoQ10 is a safe and effective treatment for children with inborn errors of
mitochondrial energy metabolism due to defects in specific respiratory chain (RC) complexes
or mitochondrial DNA (mtDNA) mutations, and that this beneficial action is reflected in
improved motor and neurobehavioral function.
Phase:
Phase 3
Details
Lead Sponsor:
University of Florida
Collaborators:
FDA Office of Orphan Products Development Food and Drug Administration (FDA)